Straits Times Index
3,110.73 +36.47 (+1.19%) Nikkei
32,307.86 -550.45 (-1.68%) Hang Seng
16,334.37 -11.52 (-0.07%) FTSE 100
7,541.24 +27.52 (+0.37%) Bitcoin USD
43,662.03 +389.71 (+0.90%) CMC Crypto 200
901.24 +8.52 (+0.95%)
Natera, Inc. (NTRA)
After hours:
| Previous close | 57.90 |
| Open | 58.01 |
| Bid | 55.50 x 1000 |
| Ask | 61.00 x 800 |
| Day's range | 56.84 - 58.06 |
| 52-week range | 35.02 - 63.00 |
| Volume | |
| Avg. volume | 1,280,577 |
| Market cap | 6.962B |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.51 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 71.87 |
Business WireNatera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
AUSTIN, Texas, December 06, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
GuruFocus.comInsider Sell Alert: Director Rowan Chapman Sells Shares of Natera Inc (NTRA)
In the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on.
Business WireNatera Announces Real-World Data Collaboration with Merck
AUSTIN, Texas, November 14, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, under which Merck will utilize Natera’s real-world database (RWD) to advance oncology research.
